...
首页> 外文期刊>Journal of viral hepatitis. >Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type
【24h】

Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type

机译:利巴韦林引发期间丙型肝炎病毒动力学根据先前的治疗反应和HCV类型而异

获取原文
获取原文并翻译 | 示例
           

摘要

The mode of action of ribavirin is not completely understood. Ribavirin monotherapy has a measurable antiviral effect, which shows great variability. It might lead to an earlier steady state of plasma concentration and therefore enhance the effect of following combination treatment. The aim of this study was to evaluate the antiviral effect of ribavirin priming and its influence on sustained virologic response after combination treatment in a group of patients with different hepatitis C virus (HCV) types with or without prior treatment experience. Retrospective analysis of 75 patients (37 treatment naive, 20 prior relapse, 16 prior nonresponse, genotype 1 present in 60 patients) from five centres who received ribavirin priming as part of an individual strategy in order to improve treatment outcome. All patients received ribavirin monotherapy with a mean dose of 14.5mgkg(-1) body weight for a mean of 28days. After ribavirin priming, dual combination treatment with pegylated interferon alfa and ribavirin was started. The mean HCV RNA decline after ribavirin priming was 0.6 log(10)IUmL(-1) (P<.001). The initial viral decline depended on HCV type and previous treatment status being highest among prior relapsers (0.8 log(10)IUmL(-1); P=.002) and HCV type 2/3 (1.2 log(10)IUmL(-1); P=.05) and lowest among those with prior nonresponse (0.3 log(10)IUmL(-1), P=.01). IFNL4 (formerly IL28B) genotype for rs12979860 and IFNL3 genotype rs8099917 did not influence the initial viral decline. The study demonstrates a significant variability in the viral dynamics and antiviral efficacy of ribavirin monotherapy, which is mainly influenced by prior treatment status. The fact that the lowest response pattern was observed in prior nonresponder patients to pegylated interferon alfa plus ribavirin combination therapy can be taken as a hint that not only the individual interferon, but also the ribavirin sensitivity contributes significantly to the nonresponsive state.
机译:病毒唑的作用方式尚未完全了解。利巴韦林单一疗法具有可测量的抗病毒作用,显示出很大的可变性。它可能导致血浆浓度更早的稳定状态,因此增强了后续联合治疗的效果。这项研究的目的是评估在具有或没有先前治疗经验的一组不同丙型肝炎病毒(HCV)患者中,联合治疗后利巴韦林引发的抗病毒作用及其对持续病毒学应答的影响。回顾性分析了来自五个中心的75例患者(37例未接受过治疗,20例先前未复发,16例先前未反应,60例患者中存在基因型1),这些患者接受利巴韦林灌注作为个体治疗策略的一部分,以改善治疗效果。所有患者均接受病毒唑单药治疗,平均剂量为14.5mgkg(-1)体重,平均28天。利巴韦林引发后,开始用聚乙二醇化干扰素α和利巴韦林双重联合治疗。利巴韦林引发后平均HCV RNA下降为0.6 log(10)IUmL(-1)(P <.001)。最初的病毒下降取决于HCV类型,先前的治疗状态在先前的复发者中最高(0.8 log(10)IUmL(-1); P = .002)和HCV类型2/3(1.2 log(10)IUmL(-1) ); P = .05),在那些先前无反应的患者中最低(0.3 log(10)IUmL(-1),P = .01)。 rs12979860的IFNL4(以前为IL28B)基因型和rs8099917的IFNL3基因型不影响最初的病毒下降。该研究表明利巴韦林单药治疗的病毒动力学和抗病毒功效存在显着差异,这主要受先前治疗状况的影响。在先前对聚乙二醇化干扰素α加利巴韦林联合治疗无反应的患者中观察到最低的反应模式这一事实可以被认为是不仅单个干扰素而且利巴韦林敏感性也显着地促进了无反应状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号